ID: ALA189217
Chembl Id: CHEMBL189217
Cas Number: 473251-81-9
PubChem CID: 11085481
Max Phase: Preclinical
Molecular Formula: C6H11O7P
Molecular Weight: 226.12
Molecule Type: Small molecule
Associated Items:
Synonyms: (S)-2-(Phosphonomethyl)Pentanedioic Acid | (2s)-2-(Phosphonomethyl)pentanedioic Acid|KYW3RS2DJY|2-PMPA, (2S)-|UNII-KYW3RS2DJY|Pentanedioic acid, 2-(phosphonomethyl)-, (2S)-|473251-81-9|G88|(S)-2-(Phosphonomethyl)Pentanedioic Acid|(S)-2-PMPA|CHEMBL189217|SCHEMBL16528808|BDBM17759|Q27460594
Canonical SMILES: O=C(O)CC[C@H](CP(=O)(O)O)C(=O)O
Standard InChI: InChI=1S/C6H11O7P/c7-5(8)2-1-4(6(9)10)3-14(11,12)13/h4H,1-3H2,(H,7,8)(H,9,10)(H2,11,12,13)/t4-/m1/s1
Standard InChI Key: ISEYJGQFXSTPMQ-SCSAIBSYSA-N
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 226.12 | Molecular Weight (Monoisotopic): 226.0242 | AlogP: -0.27 | #Rotatable Bonds: 6 |
| Polar Surface Area: 132.13 | Molecular Species: ACID | HBA: 3 | HBD: 4 |
| #RO5 Violations: ┄ | HBA (Lipinski): 7 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): ┄ |
| CX Acidic pKa: 1.79 | CX Basic pKa: ┄ | CX LogP: -1.36 | CX LogD: -9.78 |
| Aromatic Rings: ┄ | Heavy Atoms: 14 | QED Weighted: 0.46 | Np Likeness Score: 0.86 |
| 1. Tsukamoto T, Majer P, Vitharana D, Ni C, Hin B, Lu XC, Thomas AG, Wozniak KM, Calvin DC, Wu Y, Slusher BS, Scarpetti D, Bonneville GW.. (2005) Enantiospecificity of glutamate carboxypeptidase II inhibition., 48 (7): [PMID:15801825] [10.1021/jm049258g] |
| 2. Graham K, Lesche R, Gromov AV, Böhnke N, Schäfer M, Hassfeld J, Dinkelborg L, Kettschau G.. (2012) Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer., 55 (22): [PMID:23025786] [10.1021/jm300710j] |
| 3. Young JD, Ma MT, Eykyn TR, Atkinson RA, Abbate V, Cilibrizzi A, Hider RC, Blower PJ.. (2021) Dipeptide inhibitors of the prostate specific membrane antigen (PSMA): A comparison of urea and thiourea derivatives., 42 [PMID:33865971] [10.1016/j.bmcl.2021.128044] |
| 4. Zyk NY, Ber AP, Nimenko EA, Shafikov RR, Evteev SA, Petrov SA, Uspenskaya AA, Dashkova NS, Ivanenkov YA, Skvortsov DA, Beloglazkina EK, Majouga AG, Machulkin AE.. (2022) Synthesis and initial in vitro evaluation of PSMA-targeting ligands with a modified aromatic moiety at the lysine ε-nitrogen atom., 71 [PMID:35661685] [10.1016/j.bmcl.2022.128840] |
Source(1):
